Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

This study will evaluate the use of hyperpolarized 13C MRI (HP 13C MRI) and the HP-derived 13C pyruvate-to-lactate conversion rate constant (kPL) as an early response biomarker in men with treatment-naïve, high-risk, localized or locally advanced prostate cancer receiving neoadjuvant therapy.

Trial Details

NCT ID
NCT06384222
Phase
PHASE2
Sponsor
Ivan de Kouchkovsky, MD
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Abiraterone acetate
  • Prednisone
  • Hyperpolarized [1-13C] pyruvate (HP 13C)
  • Magnetic Resonance Imaging (MRI)
  • Non-investigational radical prostatectomy (RP)
  • Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Greater than or equal to 18 years of age
  • Histologically confirmed adenocarcinoma of the prostate with archival biopsy tissue (collected within 12 months of cycle 1 day 1 of treatment) avai…
  • a. Tumor tissue does not need to be retrieved but rather identified and available upon later request for future pathologic review and possible corr…
  • High-risk disease defined as meeting 1 or more of the 3 following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →